Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Amgen and Revolution Medicines stand as two distinct entities within the healthcare sector, each presenting its own set of advantages and challenges for potential investors.

Amgen, a well-established player in the biotech industry, boasts an extensive portfolio of marketed drugs and a strong track record of returning capital to shareholders. The company's focus lies in developing and manufacturing therapies for serious illnesses, particularly in the fields of oncology, inflammation, and rare diseases.

McKesson, Cencora, and Cardinal Health are the primary wholesalers for Amgen's products, accounting for nearly 77% of the company's gross revenues. This high concentration of customer dependency introduces a level of risk into the business model.

On the other hand, Revolution Medicines embodies a more speculative approach to the healthcare sector. The company is dedicated to breakthrough cancer research, but it currently lacks any revenue generation. This focus on high-stakes clinical potential comes with inherent risks, as the company's future financial success is contingent upon the successful development and approval of its experimental treatments.

Revolution Medicines' lack of current revenue contrasts sharply with Amgen's established cash flows, presenting a significant divergence in financial profiles between the two entities.

Investors must weigh these factors when deciding between Amgen and Revolution Medicines as potential additions to their portfolios in 2026. While Amgen offers the security of an established business model and a history of shareholder returns, Revolution Medicines presents the tantalizing prospect of high-stakes innovation, albeit without any current revenue.

The choice between these two healthcare stocks ultimately depends on an investor's risk tolerance, investment horizon, and appetite for speculative opportunities within the rapidly evolving biotech landscape.